{"id":"W4281861539","doi":"10.1200/jco.2022.40.16_suppl.9516","title":"Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in <i>BRAF</i><sup>V600E/K</sup>-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Dabrafenib; Medicine; Tolerability; Trametinib; Pembrolizumab; Melanoma; Placebo; Internal medicine; Adverse effect; Metastatic melanoma; Oncology; Dermatology; Vemurafenib; Cancer; Cancer research; Pathology; Immunotherapy; MAPK/ERK pathway; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007203233,0.0005055404,0.0009489164,0.0002621148,0.0003243947,0.0004904919,0.0004416786,0.0004965457,0.00371501],"category_scores_gemma":[0.000393043,0.0002915968,0.0008043725,0.0003803714,0.0002263569,0.0005582258,0.000338821,0.001530101,0.000799781],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001044799,"about_ca_system_score_gemma":0.000942673,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008148044,"about_ca_topic_score_gemma":0.002152334,"domain_scores_codex":[0.9997974,0.00005857975,0.00001556074,0.00004528549,0.00002462712,0.00005849612],"domain_scores_gemma":[0.9997471,0.00002205227,0.00006285884,0.00002224601,0.00001444192,0.0001313855],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6688108,0.02988206,0.02723933,0.001095723,0.001892895,0.0003913773,0.0001622437,0.002796179,0.05258123,0.0002268672,0.007122098,0.2077991],"study_design_scores_gemma":[0.2382108,0.6029565,0.1325509,0.0001123235,0.001657936,0.0008912576,0.00008185885,0.001307357,0.01032038,0.0002028611,0.01166763,0.00004026189],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904891,0.002346174,0.000398644,0.0001578814,0.00005896739,0.001741978,0.00195627,0.00007099663,0.002779939],"genre_scores_gemma":[0.9913588,0.0009401327,0.0006368127,0.0003256077,0.0000444068,0.001211557,0.003408151,0.00001116697,0.002063427],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00371501,"threshold_uncertainty_score":0.01242793,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05212084778346847,"score_gpt":0.3538547135369816,"score_spread":0.3017338657535131,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}